{"title":"肾脏精准医学：肾脏纤维化靶向疗法路线图。","authors":"Michael Zeisberg, Elisabeth M Zeisberg","doi":"10.1186/s13069-015-0033-x","DOIUrl":null,"url":null,"abstract":"<p><p>Based on extensive pre-clinical achievements over the past decades, it appears to be due time for a successful clinical translation in the renal fibrosis field-but what is the quickest road to get there? In light of the recent launch of the Precision Medicine Initiative and success of molecularly informed drugs in oncology, we here discuss what it may take to bring molecularly targeted anti-fibrotic to clinical use in chronic progressive kidney disease. </p>","PeriodicalId":12264,"journal":{"name":"Fibrogenesis & Tissue Repair","volume":"8 ","pages":"16"},"PeriodicalIF":0.0000,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556008/pdf/","citationCount":"0","resultStr":"{\"title\":\"Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies.\",\"authors\":\"Michael Zeisberg, Elisabeth M Zeisberg\",\"doi\":\"10.1186/s13069-015-0033-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Based on extensive pre-clinical achievements over the past decades, it appears to be due time for a successful clinical translation in the renal fibrosis field-but what is the quickest road to get there? In light of the recent launch of the Precision Medicine Initiative and success of molecularly informed drugs in oncology, we here discuss what it may take to bring molecularly targeted anti-fibrotic to clinical use in chronic progressive kidney disease. </p>\",\"PeriodicalId\":12264,\"journal\":{\"name\":\"Fibrogenesis & Tissue Repair\",\"volume\":\"8 \",\"pages\":\"16\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556008/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Fibrogenesis & Tissue Repair\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s13069-015-0033-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2015/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fibrogenesis & Tissue Repair","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13069-015-0033-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies.
Based on extensive pre-clinical achievements over the past decades, it appears to be due time for a successful clinical translation in the renal fibrosis field-but what is the quickest road to get there? In light of the recent launch of the Precision Medicine Initiative and success of molecularly informed drugs in oncology, we here discuss what it may take to bring molecularly targeted anti-fibrotic to clinical use in chronic progressive kidney disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
